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Introduction: Small cell lung cancer (SCLC) is considered an
inappropriate screening target due to its short preclinical phase and
high rate of relapse despite optimal therapy. However, while intui-
tively screening for SCLC is inadvisable, in reality, there is a
scarcity of data focusing on screen-detected SCLC and whether this
intervention leads to diagnosis at an earlier clinical stage or alters
outcome.
Methods: We conducted a retrospective review of the baseline
characteristics, treatment, and outcome of SCLC patients diagnosed
during two large-scale computed tomographic screening studies
conducted in heavy smokers.
Results: There were 7 of 4782 and 8 of 1520 cases of SCLC
identified in the Toronto and Mayo Clinic screening studies, respec-
tively. Complete clinical data were available only for 10 subjects.
The median age at diagnosis was 66 years, and 70% were female.
The majority were current smokers, with a median pack-year history
of 50 years. Four cases were detected on enrolment scan, four on
annual computed tomography scans, and two on interim scans. Four
patients had extensive disease at diagnosis. One of six limited stage
patients underwent surgical resection. All 10 patients received first-
line chemotherapy. Eight received radiation to at least one site. Eight
patients have since died. Median survival was 11.3 months. Two
patients remain disease free at 2 and 9 years, respectively.
Conclusion: This study suggests that computed tomography screen-
ing is ineffective for SCLC. Efforts to reduce mortality of SCLC
should instead focus on prevention through tobacco reduction pro-
grams, as well as the development of improved treatment options.
Key Words: Small cell lung cancer, Screening, Computed tomog-
raphy (CT), Smoking.
(J Thorac Oncol. 2011;6: 818–822)
Small cell lung cancer (SCLC) is an aggressive malignancycharacterized by a rapid doubling time and early dissem-
ination. Two-thirds of patients present with metastatic dis-
ease. As prognosis relates to T and N stage, there is some
rationale for screening to detect SCLC in heavy smokers. In
contradistinction, the short preclinical phase and high relapse
rate of SCLC suggest lack of benefit from screening.
There are few data focusing on screen-detected SCLC.
We, therefore, undertook this retrospective review of SCLC
cases diagnosed during two low-dose computed tomography
(LDCT) lung cancer screening programs conducted by the
University Health Network, Toronto, and the Mayo Clinic,
Rochester.
METHODS
Screened Population
The Toronto study enrolled 4782 individuals from 2003
to 2010. Eligibility criteria included age 50 years or older, no
previous cancer history (except nonmelanotic skin cancer),
and 10 pack-year smoking history.
The Mayo Clinic study enrolled 1520 participants aged
50 years or older with20 pack-year smoking history during
1999. Exclusion criteria included an invasive cancer diagno-
sis within 5 years (except nonmelanotic skin or localized
prostate cancer), life expectancy less than 5 years, or ineli-
gibility for pulmonary resection.
CT Screening
Methodology has been described previously.1,2 Briefly,
a LDCT thorax was performed at enrolment and annually for
4 years.
In the Toronto study, the baseline CT was positive if
indeterminate noncalcified solid nodules 5 mm or nonsolid
nodules 8 mm were identified. Management options in-
cluded: (1) immediate biopsy of nodules 15 mm, (2) anti-
biotic treatment and 1-month LDCT through nodules 15
mm, and (3) 3-month LDCT through solid nodules 5 mm.
Repeat scans were considered positive if preexisting nodules
grew or new nodules appeared.
In the Mayo Clinic study, management of nodules 4
mm included (1) urgent diagnostic CT for nodules 20 mm;
positron emission tomography, biopsy/removal considered,
(2) diagnostic CT for nodules 8 to 20 mm; CT nodule
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enhancement protocol or positron emission tomography (3)
3-month CT for nodules 4 to 7 mm. Nodules were considered
benign if stable or smaller over 2 years or benign pattern of
calcification identified. Other nodules were radiologically
indeterminate and managed by a multidisciplinary team.
Case Review
We retrospectively reviewed the records of SCLC cases
diagnosed during the two screening studies. Treatment details
were verified using the cancer centers’ databases. Survival
analysis was performed using the Kaplan Meier method. The
study was approved by the research ethics boards of Princess
Margaret Hospital and the Mayo Clinic.
RESULTS
Baseline Characteristics
Among 4782 Toronto participants, 7 of 114 diagnosed
malignancies were SCLC and treated in Princess Margaret
Hospital. Eight of 1520 Mayo Clinic study participants had
SCLC. As the majority of participants were treated at outside
institutions, complete clinical data were available for only
three patients. Thus, this review includes 10 screen-detected
SCLC patients.
Table 1 illustrates baseline patient characteristics.
There was a female preponderance (70%), with a median age
of 66 years (range, 55–75 years). As per inclusion criteria, six
were current smokers, while four were former smokers (me-
dian pack-years, 50; range, 17–70). Three patients were
asymptomatic; seven had symptoms potentially attributable
to malignancy.
CT Detection
Table 2 summarizes characteristics relating to detection
and diagnosis of SCLC. Four patients had abnormalities
leading to diagnosis on enrolment CT. In two, an immediate
biopsy was performed. The other two patients had 3-month
reimaging before biopsy.
Four cases were detected on annual scans. One patient
had a new nodule on first annual CT, which grew on scanning
1 month later. Another, who had been diagnosed with my-
eloma after enrolment scan, developed a new lung nodule on
second annual scan. This individual presented with brain
metastases while awaiting a 3-month follow-up CT. The
remaining patients were screen-detected at years 3 and 4,
respectively; the first had a 1-month CT before biopsy, the
other an immediate biopsy.
Two patients were detected on interim scanning. One
patient voluntarily withdrew from the screening study after
having two stable annual CT scans. This patient initiated a
CT thorax around the time his third annual CT was due,
leading to diagnosis. The other was diagnosed on a symptom-
initiated scan 8 months after the second annual CT.
Four patients had extensive disease (ED) at diagnosis,
while 6 had limited disease (LD). Two LD patients had mixed
SCLC and non-SCLC. All ED patients had liver metastases at
diagnosis; two had brain metastases. Four of 10 tumors were
peripherally located (Figure 1).
First-Line Treatment
Table 3 summarizes treatments received. One patient
underwent right upper lobectomy for a T1N0 tumor followed
by adjuvant cisplatin/etoposide and concurrent radiation with
prophylactic cranial radiation. All other LD patients had
nodal involvement. Of these, three received concurrent
chemoradiation; two cisplatin/etoposide, the other was
treated on a clinical trial. Two Mayo Clinic patients were
treated with chemotherapy and sequential radiation; one re-
ceived cisplatin/irinotecan, the other cisplatin/etoposide. Five
LD patients received prophylactic cranial radiation.
TABLE 1. Baseline Demographics of Small Cell Lung
Cancer Patients Detected During a Low-Dose CT Screening
Program in Heavy Smokers
Characteristic
No. of Patients
(n  10)
Sex
Male 3
Female 7
Age, yr, median (range) 66 (55–75)
Screening study participant
Toronto 7
Mayo clinic 3
Smoker
Current 6
Former 4
Pack-year smoking history, median (range) 50 (17–70)
If former smoker, median number of years since
quitting (range)
4 (1–8)
Symptoms at diagnosis
None 3
Dyspnoea 6
Cough 5
Chest pain 3
Weight loss 2
Other 3
Stage at diagnosis
Limited 6
Extensive 4
Pathology
Pure small cell 8
Mixed small cell/non-small cell 2
Tumor location
Central 6
Peripheral 4
Nodal involvement
N0 1
N1 3
N2 4
N3 2
Sites of metastases
Liver 4
Brain 2
Bone 2
Other 2
CT, computed tomography.
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Two ED patients tolerated only half the planned six
cycles of cisplatin/etoposide. The other two ED patients had
brain metastases and received whole brain radiation. One also
received palliative thoracic radiation and six cycles of cisplatin/
etoposide. The other, with renal impairment, received five
cycles of carboplatin/etoposide.
Response
Of the nine unresected patients, three with LD had
complete radiological response; one had partial response (PR)
and the other progressed. Two ED patients had PR. Another
ED patient had PR on mid-treatment scanning but progressed
TABLE 2. Characteristics Relating to Detection and
Diagnosis of Small Cell Lung Cancer Patients During a
Low-Dose CT Screening Program in Heavy Smokers
No. of Patients
(n  10)
CT of detection
Baseline 4
Annual 4
Interim 2
If detected on annual scan, number of years from
baseline scan
1 1
2 1
3 1
4 1
Recommendation after initial suspicious CT
Immediate biopsy 5
Repeat short interval imaging 5
Procedure reaching diagnosis
Bronchoscopy 3
CT-guided biopsy 4
Mediastinoscopy 2
Other 1
Staging procedures performed
CT abdomen 10
CT/MRI brain 10
Bone scan 8
Bronchoscopy 6
Mediastinoscopy 3
PET scan 3
Other 2
CT, computed tomography; MRI, magnetic resonance imaging; PET, positron
emission tomography.
FIGURE 1. Example of a peripheral screen-detected SCLC
tumor.
TABLE 3. Treatment and Outcome of Small Cell Lung
Cancer Patients Detected During a Low-Dose CT Screening
Program in Heavy Smokers
No. of Patients
(n  10)
Stage at diagnosis
Limited 6
Extensive 4
Surgical resection
Yes 1
No 9
First-line chemotherapy
Cisplatin/etoposide 7
Carboplatin/etoposide 1
Cisplatin/irinotecan 1
Other 1
Number of cycles of chemotherapy completed
3 2
4 4
5 1
6 3
First-line thoracic radiation
Radical concurrent 4
Radical sequential 2
Palliative 1
None 3
First-line brain radiation
Whole brain radiotherapy 2
Prophylactic cranial irradiation 5
None 3
Response to first-line treatment
Adjuvant 1
Complete response 3
Partial response 3
Progressive disease 3
Disease free at follow-up
Yes 2
No 8
Chemotherapy at relapse
Yes 3
No 4
Unknown 1
Radiotherapy at relapse
Yes 2
No 5
Unknown 1
CT, computed tomography.
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after cycle 5. The final ED patient had PR after two chemo-
therapy cycles but progressed after cycle 3.
Of seven patients who responded to first-line therapy,
five relapsed. Eight patients died of SCLC. Median survival,
calculated from date of pathological diagnosis, was 11.3 months
(95% CI: 3.5–19.1). Two surviving LD patients remain disease-
free 2 and 9 years from diagnosis, respectively.
DISCUSSION
Interest in lung cancer screening has increased after
recent reporting of the National Lung Cancer Screening Trial,
which showed a 20% reduction in lung cancer deaths among
smokers screened with LDCT compared with chest x-ray.3
Despite its strong association with smoking, however, SCLC
is generally considered an inappropriate screening target due
to its aggressive natural biology and early dissemination. This
study, the largest review of screen-detected SCLC reported to
date, provides supporting evidence of the ineffectiveness of
CT screening for this cancer.
Our results illustrate the short preclinical phase of
SCLC with metastases present at diagnosis in 4 of 10 cases,
with two ED patients detected on enrolment scan. The other
two ED patients developed metastases while awaiting
planned 3-month follow-up scans. This highlights the rapid
growth rate of SCLC and suggests lack of sensitivity of
LDCT for its early detection. Our findings contrast with those
of a series of five screen-detected SCLC cases in which all
had LD.4 As the planned CT schedule and follow-up recom-
mendations did not differ appreciably from our study, it is
likely this difference is due to chance.
Despite early detection, the outcome of these SCLC
patients was not significantly improved in our study. Four of
six LD patients and all ED patients relapsed, with eight
deaths from SCLC. While two study patients, including one
survivor, had combined SCLC and non-SCLC, this factor is
unlikely to have influenced outcome, as mixed histology
tumors are known to behave similarly to pure SCLC.5 The
median survival of 11.3 months in our study is not apprecia-
bly different to larger series of symptom-detected patients,
although the small sample size precludes direct comparison.
Nonetheless, considering that outside of screening less than
10% of SCLC patients are diagnosed before onset of symp-
toms, it is disappointing that earlier detection did not translate
to improved prognosis. This is particularly true when factor-
ing in the potential for lead-time bias.
The outcome of SCLC in our series contrasts sharply
with the aforementioned study, in which three of five screen-
detected SCLC patients were long-term survivors.4 All sur-
vivors had T1N0 disease and underwent surgical resection
and adjuvant chemotherapy. In contrast, our series had only
one node-negative patient who was also similarly treated but
subsequently relapsed and died. Our finding of 90% nodal
involvement at diagnosis is also higher than the 54% reported
by the International Early Lung Cancer Action Project, de-
spite similar screening techniques.6
We report that one-fifth of our SCLC tumors were
detected on interim scanning. In a previous CT screening
study of 817 patients, two SCLC cases also were detected on
interim scans, suggesting that our finding is not unique7
(Table 4).
Finally, we have shown that CT screening is inefficient
in detection of SCLC, with the number needed to screen to
detect one case being 420. The low detection rate in our study
is consistent with other international screening studies, al-
though considerable interstudy variation exists, with a ten-
dency for lower detection in studies including never or light
smokers. The only population in which CT screening of
SCLC may be justifiable is patients with Lambert-Eaton
myasthenic syndrome, as 54% subsequently are diagnosed
with SCLC.8
TABLE 4. Summary of SCLC Cases Detected During CT Screening Studies With 500 Patients in CT Screening Arm
Study
Study
Period Screening Reported
Number
Screened
Age
(yr)
Pack-Year
History SCLC Cases Detected
Nawa et al.9 1998–2000 Baseline and first annual 7956 50 No limitation 0
Sobue et al.10 1993–1998 5 yr 1611 40–79 No limitation 1 incidence
Pastorino et al.11 2000–2001 Baseline and first annual 1035 50 20 0
Diederich et al.7 1995–1999 5 yr 817 40 20 1 prevalence, 2 interim
Bastarrika et al.12 2000 onward Baseline and first annual 911 40 10 1 prevalence
Chong et al.13 1999–2003 5 yr 6406 45 20 high risk,
20 low risk
2 prevalence
Gohagan et al.14 2000 onward Baseline and first annual 1660a 55–74 30 4 NOS (CT arm)
Swensen et al.2 1999–2003 5 yr 1520 50 20 2 prevalence, 6 incidence/interim
Henschke et al.15 1993–2005 Baseline and unspecified
annual
31,567 40 No limitation 9 prevalence, 7 incidence
Sone et al.4 1996–1998 2 yr 5480 40–74 No limitation 1 interim, 4 incidence
Infante et al.16 2001–2006 Baseline 1276a 60–74 20 2 prevalence
Veronesi et al.17 2004–2006 Baseline and first annual 5202 50 20 4 prevalence, 2 incidence
Menezes et al.1 2003–2010 5 yrb 4782b 50 10 4 prevalence, 2 incidence, 1 interimb
a Number of patients randomised to CT arm of study and undergoing baseline screening CT thorax.
b Updated figures from principal investigator.
SCLC, small cell lung cancer; CT, computed tomography; NOS, not otherwise specified.
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In conclusion, this case series provides supportive ev-
idence for the widely held belief that CT screening of smok-
ers for SCLC is ineffective. Efforts to reduce mortality from
SCLC must concentrate on prevention through tobacco re-
duction programs, in addition to investing in research to assist
in the discovery of molecular markers to facilitate earlier
detection of the malignancy, as well as the development of
improved treatment.
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Erratum
GPC5 Gene and its Related Pathways in Lung Cancer: Erratum
In the article that appeared on page 2 of the January issue, one of the keywords was misspelled. The keyword should have appeared as Glypican-5. This
error has been noted in the online version of the article, which is available at www.jto.org.
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